NSE · SUPRIYA
Supriya Lifescience Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹839 Cr with net profit ₹209 Cr — a 24.91% net margin, versus 26.61% the period before.
Shareholding
As of 2026-06-30
- Promoter68.3%
- Public20.21%
- FII6.19%
- DII5.3%
82,082 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.99× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #30 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.35 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,943 Cr | 31 | 3.24 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.74 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.5 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.69 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.49 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
| Supriya Lifescience Ltd.(this company) | ₹7,384 Cr | 37.16 | 6.17 | 17.46% | 22.74% |
AI analysis
AI-generated · google/gemini-2.5-flashSupriya Lifescience Ltd. (543434) is engaged in the research, development, manufacture, and sale of bulk drugs and pharmaceutical chemicals globally. The company offers active pharmaceutical ingredients across various therapeutic areas including antihistamine, anti-allergic, anti-asthmatic, and more, as well as oncology, veterinary, and general category products. Supriya Lifescience also provides wound care solutions like GelHeal and the oral cancer detection kit, Quickblue. The company is headquartered in Mumbai, India.
Positives
- +The profit margin is high at 25.26%.
- +The Return on Capital Employed (ROCE) is healthy at 22.995%.
- +The company has a very low debt-to-equity ratio of 0.01.
- +Promoter shareholding is substantial at 68.2976% as of June 30, 2026.
- +There are no reported pledged shares by the promoters.
Negatives
- −Revenue growth information is not available in the provided data.
- −Promoter holding has seen a slight decline from 68.2813% in March 2023 to 68.2976% in June 2026, after being 68.2391% in March 2022.
- −The shareholding data for 'others' was not available for June 2026, making a complete comparison difficult.
- −Annual EPS data is not available for March 2026 in the provided annual financial records.
- −Quarterly EPS data is not available for any of the reported quarters (Dec 2024 to Mar 2026).
Business Overview
Supriya Lifescience Ltd. operates in the Pharmaceuticals sector, focusing on bulk drugs and pharmaceutical chemicals. Its product portfolio encompasses active pharmaceutical ingredients for a wide range of conditions, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti-hypertensive, vitamins, anti-malarial, and anti-gout. The company also offers specialized products like GelHeal for wound care and Quickblue for oral cancer detection, and is involved in developing new drugs across numerous therapeutic areas.
Financial Performance
The company reported annual revenue of Rs 827.87 Cr in Mar 2026. Annual net profit was Rs 209.12 Cr in Mar 2026. Quarterly revenue stood at Rs 276.53 Cr in March 2026, with a net profit of Rs 74.23 Cr for the same period. The quarterly EBIDTA was Rs 92.6 Cr in March 2026.
Profitability & Returns
Supriya Lifescience Ltd. generated a profit margin of 25.26%. The Return on Equity (ROE) was 17.46%, and the Return on Capital Employed (ROCE) was 22.995%. The Earnings Per Share (EPS) for the latest available data was Rs 26.03.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.01, indicating a limited reliance on debt financing. The book value per share is Rs 148.82. The market capitalization of the company is Rs 6950 Cr.
Ownership & Pledges
The public shareholding stands at 20.2108%. There are no reported pledged shares by the promoters.
Data as of — price: 2026-09-11 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.